Caption Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-254,563
| Closed | -$5.49M | – | 1528 |
|
|
2025
Q4 | $6.39M | Sell |
254,563
-50,437
| -17% | -$1.18M | 0.04% | 441 |
|
|
2025
Q3 | $6.9M | Buy |
305,000
+74,112
| +32% | +$1.73M | 0.05% | 387 |
|
|
2025
Q2 | $4M | Buy |
230,888
+218,888
| +1,824% | +$4.05M | 0.04% | 468 |
|
|
2025
Q1 | $262K | Buy |
+12,000
| New | +$332K | ﹤0.01% | 1223 |
|
|
2024
Q4 | – | Sell |
-216,006
| Closed | -$6.5M | – | 1442 |
|
|
2024
Q3 | $6.23M | Sell |
216,006
-213,994
| -50% | -$7.92M | 0.1% | 244 |
|
|
2024
Q2 | $16.5M | Buy |
430,000
+399,000
| +1,287% | +$18.1M | 0.25% | 83 |
|
|
2024
Q1 | $1.82M | Sell |
31,000
-362,031
| -92% | -$23.1M | 0.03% | 561 |
|
|
2023
Q4 | $23.5M | Buy |
393,031
+119,781
| +44% | +$6.08M | 0.32% | 67 |
|
|
2023
Q3 | $10.4M | Buy |
273,250
+273,026
| +121,887% | +$12M | 0.16% | 150 |
|
|
2023
Q2 | $20.4K | Buy |
+224
| New | +$19.3K | ﹤0.01% | 1030 |
|
|
2023
Q1 | – | Sell |
-17,000
| Closed | -$981K | – | 1068 |
|
|
2022
Q4 | $879K | Buy |
+17,000
| New | +$902K | 0.01% | 789 |
|
|
2022
Q1 | – | Sell |
-220,000
| Closed | -$9.71M | – | 1439 |
|
|
2021
Q4 | $10.4M | Buy |
220,000
+198,557
| +926% | +$7.82M | 0.12% | 221 |
|
|
2021
Q3 | $707K | Sell |
21,443
-49,057
| -70% | -$2.76M | 0.01% | 1132 |
|
|
2021
Q2 | $4.46M | Buy |
70,500
+65,500
| +1,310% | +$3.38M | 0.06% | 400 |
|
|
2021
Q1 | $214K | Buy |
+5,000
| New | +$237K | ﹤0.01% | 909 |
|
Other funds holding APLS
Caption Management's APLS Position: Q1 2026 in Review
Caption Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 254,563 shares — an estimated $5.49M sold.
Caption Management first reported a position in APLS in Q1 2021 and held it in 15 quarters. The position peaked at $23.5M in Q4 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Caption Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Caption Management sold 254,563 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.49M.
- Caption Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 15 quarters.
- Caption Management's Apellis Pharmaceuticals position peaked at $23.5M in Q4 2023.
- 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.